Principia Wealth Advisory’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.56K Buy
35
+3
+9% +$170 ﹤0.01% 664
2026
Q2
$2.54K Hold
32
– – ﹤0.01% 524
2026
Q1
$2.4K Buy
32
+6
+23% +$474 ﹤0.01% 464
2025
Q4
$2.06K Hold
26
– – ﹤0.01% 457
2025
Q3
$1.7K Buy
26
+1
+4% +$49 ﹤0.01% 476
2025
Q2
$988 Buy
+25
New +$818 ﹤0.01% 578
2025
Q1
– Sell
-9
Closed -$315 – 882
2024
Q4
$315 Buy
+9
New +$336 ﹤0.01% 663

Other funds holding IONS

Principia Wealth Advisory's IONS Position: Q3 2026 in Review

Principia Wealth Advisory increased its Ionis Pharmaceuticals (IONS) stake by 9.4% in Q3 2026, buying an estimated $170 and bringing the position to 35 shares worth $1.56K. The position accounts for ﹤0.01% of the portfolio, ranked #664.

Principia Wealth Advisory first reported a position in IONS in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.54K in Q2 2026. 464 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Principia Wealth Advisory held 35 shares of Ionis Pharmaceuticals worth $1.56K as of Q3 2026.
  • Principia Wealth Advisory bought 3 Ionis Pharmaceuticals shares in Q3 2026, an estimated $170.
  • Ionis Pharmaceuticals made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q3 2026, its #664 holding.
  • Principia Wealth Advisory first reported a position in Ionis Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Principia Wealth Advisory's Ionis Pharmaceuticals position peaked at $2.54K in Q2 2026.
  • 464 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Principia Wealth Advisory's 13F filing for Q3 2026, filed 12 Nov 2026.